000			01634 a2200469 4500
005			20250515183412.0
264		0	_c20091030
008			200910s 0 0 eng d
022			_a1352-4585
024	7		_a10.1177/1352458509106543 _2doi
040			_aNLM _beng _cNLM
100	1		_aWeber-Schoendorfer, C
245	0	0	_aMultiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. _h[electronic resource]
260			_bMultiple sclerosis (Houndmills, Basingstoke, England) _cSep 2009
300			_a1037-42 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAbortion, Spontaneous _xepidemiology
650	0	4	_aAdolescent
650	0	4	_aAdult
650	0	4	_aBirth Weight
650	0	4	_aCohort Studies
650	0	4	_aCongenital Abnormalities _xepidemiology
650	0	4	_aFemale
650	0	4	_aGlatiramer Acetate
650	0	4	_aHumans
650	0	4	_aImmunologic Factors _xtherapeutic use
650	0	4	_aInfant, Newborn
650	0	4	_aInterferon beta-1a
650	0	4	_aInterferon beta-1b
650	0	4	_aInterferon-beta _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMultiple Sclerosis _xdrug therapy
650	0	4	_aPeptides _xtherapeutic use
650	0	4	_aPregnancy
650	0	4	_aPregnancy Outcome _xepidemiology
650	0	4	_aRisk Factors
650	0	4	_aYoung Adult
700	1		_aSchaefer, C
773	0		_tMultiple sclerosis (Houndmills, Basingstoke, England) _gvol. 15 _gno. 9 _gp. 1037-42
856	4	0	_uhttps://doi.org/10.1177/1352458509106543 _zAvailable from publisher's website
999			_c19095060 _d19095060